Home Investing Here’s why Bristol Myers quarter wasn’t enough to change our view on the stock

Here’s why Bristol Myers quarter wasn’t enough to change our view on the stock

by admin

The company’s future hinges on the success of Cobenfy, the company’s new schizophrenia drug.

You may also like

Leave a Comment

four × 3 =